Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Personalized Treatment Response Assessment for Rare Childhood Tumors Using Microcalorimetry-Exemplified by Use of Carbonic Anhydrase IX and Aquaporin 1 Inhibitors.

Gros SJ, Holland-Cunz SG, Supuran CT, Braissant O.

Int J Mol Sci. 2019 Oct 9;20(20). pii: E4984. doi: 10.3390/ijms20204984.

2.

Intestinal IMINO transporter SIT1 is not expressed in human newborns.

Meier C, Camargo SM, Hunziker S, Moehrlen U, Gros SJ, Bode P, Leu S, Meuli M, Holland-Cunz S, Verrey F, Vuille-Dit-Bille RN.

Am J Physiol Gastrointest Liver Physiol. 2018 Nov 1;315(5):G887-G895. doi: 10.1152/ajpgi.00318.2017. Epub 2018 Aug 30.

PMID:
30160974
3.

CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target.

Drenckhan A, Freytag M, Supuran CT, Sauter G, Izbicki JR, Gros SJ.

J Enzyme Inhib Med Chem. 2018 Dec;33(1):1024-1033. doi: 10.1080/14756366.2018.1475369.

4.

Increased regulatory T cells in pediatric acute appendicitis.

Sucic L, Galati-Fournier V, Kym U, Pfeifle VA, Gros SJ, Schäfer KH, Holland-Cunz S, Keck S.

Pediatr Allergy Immunol. 2018 Feb;29(1):104-108. doi: 10.1111/pai.12797. Epub 2017 Oct 30. No abstract available.

PMID:
28881058
5.

Water permeability is a measure of severity in acute appendicitis.

Pini N, Pfeifle VA, Kym U, Keck S, Galati V, Holland-Cunz S, Gros SJ.

J Enzyme Inhib Med Chem. 2017 Dec;32(1):1036-1041. doi: 10.1080/14756366.2017.1347167.

6.

Regenerative Capacity of the Enteric Nervous System after Ileoileal Anastomoses in a Rat Model.

Pfeifle VA, Gros SJ, Frongia G, Schäfer KH, Holland-Cunz S.

Eur J Pediatr Surg. 2017 Apr;27(2):200-205. doi: 10.1055/s-0036-1586200. Epub 2016 Jul 27.

PMID:
27464355
7.

Influence of hypoxia-dependent factors on the progression of neuroblastoma.

Ameis HM, Drenckhan A, Freytag M, Izbicki JR, Supuran CT, Reinshagen K, Holland-Cunz S, Gros SJ.

Pediatr Surg Int. 2016 Feb;32(2):187-92. doi: 10.1007/s00383-015-3831-8. Epub 2015 Oct 28.

PMID:
26510737
8.

Carbonic anhydrase IX correlates with survival and is a potential therapeutic target for neuroblastoma.

Ameis HM, Drenckhan A, Freytag M, Izbicki JR, Supuran CT, Reinshagen K, Holland-Cunz S, Gros SJ.

J Enzyme Inhib Med Chem. 2016;31(3):404-9. doi: 10.3109/14756366.2015.1029471. Epub 2015 Apr 17.

PMID:
25884234
9.

ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts.

Kebenko M, Drenckhan A, Gros SJ, Jücker M, Grabinski N, Ewald F, Grottke A, Schultze A, Izbicki JR, Bokemeyer C, Wellbrock J, Fiedler W.

Cell Signal. 2015 Feb;27(2):373-81. doi: 10.1016/j.cellsig.2014.11.022. Epub 2014 Nov 27.

PMID:
25435423
10.

Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.

Drenckhan A, Grob T, Dupree A, Dohrmann T, Mann O, Izbicki JR, Gros SJ.

Langenbecks Arch Surg. 2014 Oct;399(7):879-88. doi: 10.1007/s00423-014-1235-1. Epub 2014 Jul 29.

PMID:
25070024
11.

PGK1 as predictor of CXCR4 expression, bone marrow metastases and survival in neuroblastoma.

Ameis HM, Drenckhan A, von Loga K, Escherich G, Wenke K, Izbicki JR, Reinshagen K, Gros SJ.

PLoS One. 2013 Dec 20;8(12):e83701. doi: 10.1371/journal.pone.0083701. eCollection 2013.

12.

Effective inhibition of metastases and primary tumor growth with CTCE-9908 in esophageal cancer.

Drenckhan A, Kurschat N, Dohrmann T, Raabe N, Koenig AM, Reichelt U, Kaifi JT, Izbicki JR, Gros SJ.

J Surg Res. 2013 Jun 15;182(2):250-6. doi: 10.1016/j.jss.2012.09.035. Epub 2012 Oct 10.

PMID:
23117118
13.

Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer.

Gros SJ, Kurschat N, Drenckhan A, Dohrmann T, Forberich E, Effenberger K, Reichelt U, Hoffman RM, Pantel K, Kaifi JT, Izbicki JR.

PLoS One. 2012;7(10):e47287. doi: 10.1371/journal.pone.0047287. Epub 2012 Oct 17. Erratum in: PLoS One. 2013;8(5). doi: 10.1371/annotation/5dafa9a8-2e6d-4487-b35f-7126141fe00e.

14.

CXCR4/SDF-1α-mediated chemotaxis in an in vivo model of metastatic esophageal carcinoma.

Gros SJ, Graeff H, Drenckhan A, Kurschat N, Blessmann M, Rawnaq T, Izbicki JR.

In Vivo. 2012 Jul-Aug;26(4):711-8.

PMID:
22773586
15.

Orthotopic models of esophageal carcinoma and their use in drug discovery.

Gros SJ.

Curr Protoc Pharmacol. 2011 Sep;Chapter 14:Unit14.20. doi: 10.1002/0471141755.ph1420s54.

PMID:
21898333
16.

L1 is highly expressed in tumors of the nervous system: a study of over 8000 human tissues.

Rawnaq T, Quaas A, Zander H, Gros SJ, Reichelt U, Blessmann M, Wilzcak W, Schachner M, Sauter G, Izbicki JR, Kaifi JT.

J Surg Res. 2012 Apr;173(2):314-9. doi: 10.1016/j.jss.2010.10.029. Epub 2010 Nov 21.

PMID:
21195422
17.

Orthotopic fluorescent peritoneal carcinomatosis model of esophageal cancer.

Gros SJ, Dohrmann T, Rawnaq T, Kurschat N, Bouvet M, Wessels J, Hoffmann RM, Izbicki JR, Kaifi JT.

Anticancer Res. 2010 Oct;30(10):3933-8.

PMID:
21036705
18.

Effective therapeutic targeting of the overexpressed HER-2 receptor in a highly metastatic orthotopic model of esophageal carcinoma.

Gros SJ, Kurschat N, Dohrmann T, Reichelt U, Dancau AM, Peldschus K, Adam G, Hoffman RM, Izbicki JR, Kaifi JT.

Mol Cancer Ther. 2010 Jul;9(7):2037-45. doi: 10.1158/1535-7163.MCT-10-0209. Epub 2010 Jul 6.

19.

Complementary use of fluorescence and magnetic resonance imaging of metastatic esophageal cancer in a novel orthotopic mouse model.

Gros SJ, Dohrmann T, Peldschus K, Schurr PG, Kaifi JT, Kalinina T, Reichelt U, Mann O, Strate TG, Adam G, Hoffman RM, Izbicki JR.

Int J Cancer. 2010 Jun 1;126(11):2671-81. doi: 10.1002/ijc.24980.

20.

Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus.

Reichelt U, Duesedau P, Tsourlakis MCh, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, Simon R, Izbicki JR, Sauter G.

Mod Pathol. 2007 Jan;20(1):120-9. Epub 2006 Nov 24.

Supplemental Content

Support Center